PTPRG and chronic myelogenous leukemia, BCR-ABL1 positive: Moreover, the hurdle of developing therapeutic monoclonal antibodies against CML may be overcome by evolving promising detection tools, as TPγ B9-2 towards protein tyrosine phosphatase receptor gamma (PTPRG) [62].